

JosÃ© Vicente FernÃ¡ndez-Montero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8114393/publications.pdf>

Version: 2024-02-01

20
papers

414
citations

759055

12
h-index

839398

18
g-index

20
all docs

20
docs citations

20
times ranked

681
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 58, 1549-1553.	2.9	85
2	Hepatitis C therapy with HCV NS5B polymerase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1161-1170.	0.9	57
3	Update on HIV/HCV Coinfection. <i>Current HIV/AIDS Reports</i> , 2013, 10, 226-234.	1.1	48
4	HIV protease inhibitors: recent clinical trials and recommendations on use. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1615-1629.	0.9	38
5	Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. <i>Aids</i> , 2013, 27, 1129-1134.	1.0	24
6	Towards hepatitis C eradication from the HIV-infected population. <i>Antiviral Research</i> , 2014, 105, 1-7.	1.9	24
7	Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV hepatitis C virus coinfecting patients. <i>Aids</i> , 2013, 27, 1187-1188.	1.0	22
8	Emerging antiretroviral drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 211-219.	0.9	19
9	Long-term survival and liver-related events after peginterferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2014, 20, 65-72.	0.6	16
10	Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1007-1014.	0.9	14
11	Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 517-530.	1.0	14
12	Predicted effect of direct acting antivirals in the current HIV hepatitis C-coinfecting population in Spain. <i>Antiviral Therapy</i> , 2011, 17, 571-575.	0.6	13
13	Dolutegravir, abacavir and lamivudine as HIV therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1051-1057.	0.9	10
14	Antiretroviral drugs for pre-exposure prophylaxis of HIV infection. <i>AIDS Reviews</i> , 2012, 14, 54-61.	0.5	10
15	Progression to advanced liver fibrosis in HIV/HCV-coinfecting patients and prioritization of new hepatitis C therapies. <i>Antiviral Therapy</i> , 2014, 19, 799-803.	0.6	9
16	Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 931-948.	1.9	7
17	Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2013, 12, 269-275.	0.3	3
18	Long-term treatment of patients with HIV-1: the role of atazanavir. <i>HIV/AIDS - Research and Palliative Care</i> , 2010, 2, 157.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Author's response: expert reviews: who are they for?. Expert Opinion on Pharmacotherapy, 2012, 13, 1217-1218.	0.9	0
20	Once-daily raltegravir moving ahead. AIDS Reviews, 2013, 15, 238-9.	0.5	0